Applied Therapeutics Inc

$3.17 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Applied Therapeutics Inc

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Stock Analysis

last close $3.4
1-mo return -64%
3-mo return -80%
avg daily vol. 678.24T
52-week high 29.8
52-week low 3.35
market cap. $103M
forward pe -
annual div. -
roe -107.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 78.3%
baraka

Subscribe now for daily local and international financial news

Subscribe